Immunome, Inc.
NASDAQIMNM heads into the final week of September with shorts rebuilding, options sentiment flipping sharply negative, and the stock down 15% on the week to $21.89, all while a unanimous analyst buy consensus sits 65% above the current price. The most striking shift this week is in options positioning, where the market has moved meaningfully more defensive. The put/call ratio has climbed…
Snapshot as of 7 Oct 2026
IMNM heads into the final week of September with shorts rebuilding, options sentiment flipping sharply negative, and the stock down 15% on the week to $21.89, all while a unanimous analyst buy consensus sits 65% above…
Immunome walks into its August 13 earnings report with two analyst target raises landing on the same morning — a signal that at least part of the Street is growing more constructive even as insiders continue to sell…
Immunome heads into its August 13 earnings report with a clear tension: the stock is drifting higher while nearly every insider who can sell, is selling. The insider activity is the standout signal. Over the past 90…
Immunome heads into the week with a striking split: the stock is up 15% in five days, but insiders are selling into every uptick while short sellers are holding their ground. The insider activity tells the most urgent…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IMNM — free to start on ORTEX.
Sign up for free →Open IMNM on ORTEX